Key result
Remote monitoring for cardiovascular implantable electronic devices was cost-effective in Japan, yielding Incremental Cost-Effectiveness Ratios between 311,111 JPY and 1,220,000 JPY per QALY gained, well below the 5 million JPY threshold.
Why the study?
Although remote monitoring for CIEDs was recommended and gained reimbursement in Japan, its cost-effectiveness evaluation had not been sufficient.
Does remote monitoring improve cost-effectiveness compared to standard in-hospital follow-up in patients with cardiovascular implantable electronic devices?
Systematic Review (n=491)
Does remote monitoring improve cost-effectiveness compared to standard in-hospital follow-up in patients with cardiovascular implantable electronic devices?
Effect estimate: ICERs of 311,111 JPY, 569,697 JPY, and 1,220,000 JPY
Remote monitoring for cardiovascular implantable electronic devices is highly cost-effective in Japan, with ICERs well below the national threshold.
Supports adoption of remote monitoring for CIEDs in Japan; confirms cost-effectiveness below national thresholds in systematic analyses.
BACKGROUND: 2018 revision of the health insurance reimbursement in Japan brought additional fee for Cardiovascular Implantable Electronic Devices (CIEDs) Management by Remote Monitoring. The adaption of CIEDs Remote Monitoring has already been recommended by the societies, but the cost-effectiveness evaluation about the system has not been enough. This research was designed, therefore, to evaluate the cost-effectiveness about CIEDs Remote Monitoring in Japan. METHODS: A systematic review was conducted along with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Certain criteria and search strategy were pre-defined to identify studies that could be included into this research. The process of the quality assessments was planned by Critical Appraisal Skills Programme (CASP). Quality Adjusted Life Years (QALYs) that were extracted from the included studies would be calculated into Incremental Cost-Effectiveness Ratio (ICER) with the reimbursement amount in Japan. RESULTS: Three studies met the systematic review criteria after the selection along with PRISMA flow diagram. The quality of the included studies was assured by CASP Checklists designed for RCT and Cohort Study. ICERs from the selected studies were provided as 569,697 JPY, 1,220,000 JPY, and 311, 111 JPY for the patient groups enrolled with Remote Monitoring system. CONCLUSION: ICERs for CIEDs Remote Monitoring were demonstrated as the cost-effective under the threshold set by Central Social Insurance Medical Council (Chuikyo). As this study put the validity of the cost-effectiveness approach in a certain field in Japan, this kind of evaluation should be performed on more areas along with the guideline by Chuikyo.
No takes yet. Share an insight, caveat, or question.
Tomoya Shirane (2019) conducted a systematic review in Cardiovascular Implantable Electronic Devices (CIEDs) (n=491). Remote Monitoring vs. Standard in-hospital follow-up was evaluated on Incremental Cost-Effectiveness Ratio (ICER) (ICERs of 311,111 JPY, 569,697 JPY, and 1,220,000 JPY). Remote monitoring for cardiovascular implantable electronic devices was cost-effective in Japan, yielding Incremental Cost-Effectiveness Ratios between 311,111 JPY and 1,220,000 JPY per QALY gained, well below the 5 million JPY threshold.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: